Review



caf inhibitor talabostat  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress caf inhibitor talabostat
    <t>Talabostat</t> mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.
    Caf Inhibitor Talabostat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/caf inhibitor talabostat/product/MedChemExpress
    Average 95 stars, based on 42 article reviews
    caf inhibitor talabostat - by Bioz Stars, 2026-03
    95/100 stars

    Images

    1) Product Images from "SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts"

    Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    Journal: Cancer Research

    doi: 10.1158/0008-5472.CAN-24-4916

    Talabostat mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.
    Figure Legend Snippet: Talabostat mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Staining



    Similar Products

    crl 8303 bsl 1 caf  (ATCC)
    99
    ATCC crl 8303 bsl 1 caf
    Crl 8303 Bsl 1 Caf, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 8303 bsl 1 caf/product/ATCC
    Average 99 stars, based on 1 article reviews
    crl 8303 bsl 1 caf - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    caf inhibitor talabostat  (MedChemExpress)
    95
    MedChemExpress caf inhibitor talabostat
    <t>Talabostat</t> mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.
    Caf Inhibitor Talabostat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/caf inhibitor talabostat/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    caf inhibitor talabostat - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    fibroblasts pcaf  (ATCC)
    94
    ATCC fibroblasts pcaf
    <t>Talabostat</t> mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.
    Fibroblasts Pcaf, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fibroblasts pcaf/product/ATCC
    Average 94 stars, based on 1 article reviews
    fibroblasts pcaf - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    cafs  (Miltenyi Biotec)
    94
    Miltenyi Biotec cafs
    <t>Talabostat</t> mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.
    Cafs, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cafs/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    cafs - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    fibroblasts cafs  (ATCC)
    99
    ATCC fibroblasts cafs
    <t>Talabostat</t> mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.
    Fibroblasts Cafs, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fibroblasts cafs/product/ATCC
    Average 99 stars, based on 1 article reviews
    fibroblasts cafs - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    crl 2539 mouse caf bayer  (ATCC)
    99
    ATCC crl 2539 mouse caf bayer
    <t>Talabostat</t> mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.
    Crl 2539 Mouse Caf Bayer, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 2539 mouse caf bayer/product/ATCC
    Average 99 stars, based on 1 article reviews
    crl 2539 mouse caf bayer - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    cafs  (MedChemExpress)
    99
    MedChemExpress cafs
    <t>Talabostat</t> mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.
    Cafs, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cafs/product/MedChemExpress
    Average 99 stars, based on 1 article reviews
    cafs - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    prostate cancer  (ATCC)
    94
    ATCC prostate cancer
    <t>Talabostat</t> mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.
    Prostate Cancer, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/prostate cancer/product/ATCC
    Average 94 stars, based on 1 article reviews
    prostate cancer - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Talabostat mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.

    Journal: Cancer Research

    Article Title: SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts

    doi: 10.1158/0008-5472.CAN-24-4916

    Figure Lengend Snippet: Talabostat mesylate reverses CRLM progression and synergizes with PD-1/PD-L1 blockade therapy. A, Schematic of the subcutaneous mouse model established with MC38 cells. B–D, Representative tumor morphology, weight, and volume ( n = 5 mice/group). E, ELISA measured the IFNγ, granzyme B, and TGFβ levels in the tumor tissues. F, Schematic representation of the colorectal cancer (CRC) PDX model in PBMC-reconstituted NOG mice. G–I, Tumor morphology, weight, and volume data ( n = 5 mice/group). J, ELISA measured the SPP1, IFNγ, granzyme B, and TGFβ levels in the tumor tissues. K and L, Hematoxylin and eosin staining of metastatic livers from C57BL/6J mice implanted with MC38-GFP or MC38-SPP1 cells, treated with talabostat mesylate, showed liver weight and tumor burden ( n = 5 mice/group). Scale bar, 1 mm. M and N, Flow cytometric analysis of the IFNγ + CD8 + and GZMB + CD8 + T-cell populations in liver metastases ( n = 5 mice/group). Results are presented as mean ± SEM. P values were determined via one-way ANOVA ( D , E , H , J , and L–N ). *, P < 0.05; **, P < 0.01; ***, P < 0.001. aP, anti–PD-1 antibody; aP + i, anti–PD-1 antibody + talabostat mesylate.

    Article Snippet: Additionally, the β-catenin inhibitor MSAB (cat. #HY-120697) and the CAF inhibitor talabostat (cat. #HY-13233) were sourced from MedChemExpress.

    Techniques: Enzyme-linked Immunosorbent Assay, Staining